Kwality Pharmaceuticals Ltd Stock Price Today (NSE: KPL)
Fundamental Score
Kwality Pharmaceuticals Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Kwality Pharmaceuticals Ltd share price today is ₹1452.60, up +0.00% on NSE/BSE as of 18 February 2026. Kwality Pharmaceuticals Ltd (KPL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹958.14 (Cr). The 52-week high for KPL share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 19.53x, KPL is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 16.31% and a debt-to-equity ratio of 0.38.
Kwality Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Kwality Pharmaceuticals Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Kwality Pharmaceuticals Share Price: A Financial Stability Analysis
The pharmaceutical industry, currently navigating a landscape of increasing generic competition and stringent regulatory scrutiny, demands a keen eye on financial stability. This analysis examines the financial health of Kwality Pharmaceuticals Ltd, focusing on key metrics relevant to its long-term viability. The current Kwality Pharmaceuticals share price stands at ₹1157.650024, with a Price-to-Earnings (PE) ratio of 19.53 and a Return on Capital Employed (ROCE) of 18.4%. This assessment forms part of a comprehensive 80-parameter fundamental audit, verified by Sweta Mishra.
The PE ratio of 19.53 suggests that investors are willing to pay ₹19.53 for every rupee of Kwality Pharmaceuticals' earnings. When comparing to its peers, a more holistic picture emerges. For example, assessing management quality, while subjective, is crucial.
Mankind Pharma Ltd often boasts a management team lauded for their strategic execution and market understanding, whereas Kwality Pharmaceuticals requires deeper scrutiny to ascertain similar levels of expertise and forward-thinking leadership. This qualitative assessment, while challenging to quantify, significantly impacts long-term growth prospects.The ROCE of 18.4% is a significant indicator of Kwality Pharmaceuticals' efficiency in generating profits from its capital investments. This strong ROCE contributes directly to the company's "moat," or its competitive advantage. A higher ROCE suggests that the company can reinvest its earnings at a favorable rate, further strengthening its position and potentially deterring competitors. It also implies efficient resource allocation and effective operational management.
While the presented data offers valuable insights, it's crucial to remember that this analysis is based solely on the available metrics and is purely observational. A thorough understanding of Kwality Pharmaceuticals' financial stability necessitates a deeper dive into its balance sheet, cash flow statement, and overall market dynamics. This includes evaluating debt levels, inventory management practices, and future growth strategies within the competitive pharmaceutical landscape.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Kwality Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of KPL across key market metrics for learning purposes.
Positive Indicators
13 factors identified
Strong Return on Equity (16.31%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (18.40%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (24.78%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 19.53 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (66.71%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (23.35%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (21.59% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (37.04% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (37.04% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Strong Interest Coverage (7.41x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹49.52 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (54.83%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Limited Institutional Interest (FII+DII: 0.33%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Kwality Pharmaceuticals Ltd Financial Statements
Comprehensive financial data for Kwality Pharmaceuticals Ltd including income statement, balance sheet and cash flow
About KPL (Kwality Pharmaceuticals Ltd)
Kwality Pharmaceuticals Ltd (KPL) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹958.14 (Cr). Kwality Pharmaceuticals Ltd has delivered a Return on Equity (ROE) of 16.31% and a ROCE of 18.40%. The debt-to-equity ratio stands at 0.38, reflecting the company's capital structure. Investors tracking KPL share price can monitor key metrics including P/E ratio, promoter holding of 54.83%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
Latest News
KPL Share Price: Frequently Asked Questions
What is the current share price of Kwality Pharmaceuticals Ltd (KPL)?
As of 18 Feb 2026, 10:41 am IST, Kwality Pharmaceuticals Ltd share price is ₹1452.60. The KPL stock has a market capitalisation of ₹958.14 (Cr) on NSE/BSE.
Is KPL share price Overvalued or Undervalued?
KPL share price is currently trading at a P/E ratio of 19.53x, compared to the industry average of 31.77x. Based on this relative valuation, the Kwality Pharmaceuticals Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of KPL share price?
The 52-week high of KPL share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Kwality Pharmaceuticals Ltd share price?
Key factors influencing KPL share price include quarterly earnings growth (Sales Growth: 23.35%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Kwality Pharmaceuticals Ltd a good stock for long-term investment?
Kwality Pharmaceuticals Ltd shows a 5-year Profit Growth of 37.04% and an ROE of 16.31%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.38 before investing in KPL shares.
How does Kwality Pharmaceuticals Ltd compare with its industry peers?
Kwality Pharmaceuticals Ltd competes with major peers in the Pharmaceuticals. Investors should compare KPL share price P/E of 19.53x and ROE of 16.31% against the industry averages to determine competitive standing.
What is the P/E ratio of KPL and what does it mean?
KPL share price has a P/E ratio of 19.53x compared to the industry average of 31.77x. Investors pay ₹20 for every ₹1 of annual earnings.
How is KPL performing according to Bull Run's analysis?
KPL has a Bull Run fundamental score of 69.7/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does KPL belong to?
KPL operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Kwality Pharmaceuticals Ltd share price.
What is Return on Equity (ROE) and why is it important for KPL?
KPL has an ROE of 16.31%, which indicates excellent management efficiency. ROE measures how efficiently Kwality Pharmaceuticals Ltd generates profits from shareholders capital.
How is KPL debt-to-equity ratio and what does it indicate?
KPL has a debt-to-equity ratio of 0.38, which indicates moderate leverage that should be monitored.
What is KPL dividend yield and is it a good dividend stock?
KPL offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Kwality Pharmaceuticals Ltd shares.
How has KPL share price grown over the past 5 years?
KPL has achieved 5-year growth rates of: Sales Growth 21.59%, Profit Growth 37.04%, and EPS Growth 37.04%.
What is the promoter holding in KPL and why does it matter?
Promoters hold 54.83% of KPL shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Kwality Pharmaceuticals Ltd.
What is KPL market capitalisation category?
KPL has a market capitalisation of ₹958 crores, placing it in the Small-cap category.
How volatile is KPL stock?
KPL has a beta of N/A. A beta > 1 suggests the Kwality Pharmaceuticals Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is KPL operating profit margin trend?
KPL has a 5-year average Operating Profit Margin (OPM) of 24.78%, indicating the company's operational efficiency.
How is KPL quarterly performance?
Recent quarterly performance shows Kwality Pharmaceuticals Ltd YoY Sales Growth of 23.35% and YoY Profit Growth of 66.71%.
What is the institutional holding pattern in KPL?
KPL has FII holding of 0.00% and DII holding of 0.33%. Significant institutional holding often suggests professional confidence in the Kwality Pharmaceuticals Ltd stock.